MILFORD, Mass., April 16, 2012 /PRNewswire/ -- PLC Systems Inc. (OTCBB: PLCSF) today announced that its CEO, Mark Tauscher, was featured in an interview on www.corporateprofile.com, a financial news source providing stock and market information. The interview can also be accessed on PLC Systems' website: http://plcmed.com/Educational-Resources-Interviews.asp. "We are always seeking additional opportunities to present our company, including through vehicles like Corporate Profile(R). For PLC, Corporate Profile(R)'s platform provides another great venue for us to get PLC's name, and our progress with our lead product, RenalGuard(R), in front of the public," said Mark Tauscher, President and CEO of PLC Systems. "We are pleased to present a platform for emerging companies with exciting stories like PLC Systems to those that frequent our sites," said Laurel Moody, CEO of Corporate Profile(R). About Corporate Profile(R) CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in a unique platform for investors to receive today's hottest tips and market info. For more info please visit: www.corporateprofile.com and www.cpreports.comAbout PLC Systems PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC. PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc. Contact: Mary T. Conway 508-520-2545 email@example.com SOURCE PLC Systems Inc.